In this issue:
Third-generation EGFR mutant-selective inhibitor in advanced NSCLC
TKI activity in NSCLC with uncommon EGFR mutations
Immune biomarkers and response to ICIs in BRAFV600 and BRAF non-V600 altered lung cancer
Tepotinib in METex14 skipping NSCLC
Abivertinib for EGFR T790M-mutant NSCLC
Carboplatin-paclitaxel ±bevacizumab in advanced pulmonary sarcomatoid carcinoma
First-line nivolumab/ipilimumab + chemotherapy in advanced NSCLC
Adding camrelizumab to carboplatin/paclitaxel in advanced squamous NSCLC
Lazertinib for advanced EGFR T790M-positive NSCLC after EGFR TKI
Continuing lorlatinib beyond disease progression in ALK-positive NSCLC
Please login below to download this issue (PDF)